Performance comparison of intelligent recurrence-risk stratification software based on 2009 American Thyroid Association guidelines and 2014 Chinese guidelines for 131I therapy of differentiated thyroid carcinoma
10.3760/cma.j.issn.2095-2848.2018.04.010
- VernacularTitle:基于2009版美国甲状腺协会指南及2014版中国指南的分化型甲状腺癌术后复发风险分层软件的应用比较
- Author:
Houyang HU
1
;
Jun LIANG
;
Teng ZHANG
;
Hui LI
;
Yanqing LIU
;
Yansong LIN
Author Information
1. 100730,中国医学科学院、北京协和医学院北京协和医院核医学科
- Keywords:
Thyroid neoplasms;
Prognosis;
Neoplasm recurrence,local;
Practice guideline;
United States;
China
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2018;38(4):271-273
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare two recurrence-risk stratification software (RSS),which could evaluate the recurrence-risk in patients with differentiated thyroid carcinoma (DTC) intelligently.Methods Based on 2009 American Thyroid Association (ATA) guidelines and clinical guidelines for 131I therapy of DTC patients in China (2014),two RSS (RSS1 and RSS2) were designed.From January 2013 to January 2016,1 043 non-metastasis DTC patients (386 males,657 females;average age (46.4±10.5) years) in Peking Union Medical College Hospital were involved to be risk-stratified,and the results were evaluated by ATA response evaluation system.x2 test was used to analyze the data.Results With 2 years' (median) follow-up,the recurrence rates in low,intermediate and high recurrence-risk groups evaluated by RSS1 were 2.8％(1/36),4.7％ (34/725) and 42.9％ (121/282),and those were 0(0/29),3.7％ (26/698) and 41.1％(130/316) evaluated by RSS2.The recurrence rate was lower in low-risk group evaluated by RSS2 than that by RSS1,but there was no significant difference (x2=3.046,P＞0.05).More patients with recurrence were divided into high-risk group evaluated by RSS2,but the recurrence rates of 2 high-risk groups evaluated by RSS1 and RSS2 were not significantly different (x2 =0.082,P＞0.05).Conclusion RSS1 and RSS2 could predict recurrence-risk effectively,and RSS2 could classify more recurrent patients into high-risk group.
